{"id":"stn1012600-ophthalmic-solution-0-002","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Corticosteroids like STN1012600 work by inhibiting the production of inflammatory mediators, thereby reducing swelling and pain in the eye. This makes it an effective treatment for various ocular conditions. The exact mechanism of action involves the suppression of phospholipase A2, which is involved in the production of inflammatory eicosanoids.","oneSentence":"STN1012600 ophthalmic solution 0.002% is a corticosteroid used to reduce inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:40.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT05503901","phase":"PHASE3","title":"A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-08","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":131},{"nctId":"NCT05495061","phase":"PHASE3","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":325},{"nctId":"NCT05905653","phase":"PHASE1","title":"Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2023-05-25","conditions":"Healthy Adult Males Volunteers","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"STN1012600 ophthalmic solution 0.002%","genericName":"STN1012600 ophthalmic solution 0.002%","companyName":"Santen Pharmaceutical Co., Ltd.","companyId":"santen-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STN1012600 ophthalmic solution 0.002% is a corticosteroid used to reduce inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}